We read with interest the article entitled ''Changes in small dense low-density lipoprotein levels following acute coronary syndrome'' by Emadzadeh et al. 1 They compared the baseline small dense low-density lipoprotein (sdLDL) levels in healthy controls and in patients with acute coronary syndrome (ACS) and reported the changes in sdLDL levels 24 hours following ACS. Patients with ACS had a higher concentration of sdLDL compared with controls, and the changes in sdLDL levels were not significantly different between the patients with myocardial infarction and unstable angina.
As the authors 1 mentioned, others have reported a positive association between sdLDL levels and presence and severity of coronary artery disease. 2 Conditions such as metabolic syndrome, hyperinsulinemia, hypertriglyceridemia, increased waist-to-hip ratio, low-serum high-density lipoprotein 2, and systolic hypertension affect sdLDL levels. As the low-density lipoprotein (LDL)-cholesterol concentration is not always raised in patients with ACS, sdLDL may be an emerging risk factor. Fukushima et al 3 suggested that sdLDL might be a useful treatment marker in patients with ACS.
In the current study, 1 blood samples were collected on hospital admission and approximately 24 hours later when the sdLDL levels did not alter significantly. As heparin markedly alters lipoprotein profiles 4 and a bolus of high-dose heparin may be given to patients with ACS, samples obtained 24 hours following ACS may be affected. Hirayama et al also observed that sdLDL levels exhibit circadian changes in both diabetic patients and controls. In both the groups, the sdLDL concentrations were highest early in the morning and decreased during the day. 5 The sdLDL might be a useful treatment marker in patients with ACS, and it would be worthwhile to monitor the sdLDL levels for longer duration and to consider the circadian changes when dealing with changes in sdLDL levels following ACS. Further large-scale prospective studies are needed to define the exact relationship between ACS and alterations in LDL subclasses.
